Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018 /
Highlights in SCLC from ESMO 2018

19th - 23rd Oct 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 851

Dr Noemi Reguart - University of Barcelona, Barcelona, Spain

Dr Reguart speaks with ecancer at ESMO 2018 in Munich about highlights from the ESMO session she moderated on small cell lung cancer.

She highlights work with new targeted therapies, including checkpoint combinations, antibodantibody-drugates and lurbinectidin as opening treatment options in a disease which has not seen the same breakthroughs as non-small cell lung cancer.

Looking to the future, Dr Reguart considers how these drugs may synergise in immuno-chemo combinations, and the importance of treatment staging and sequencing.

For more lung cancer news, Dr Federico Capuzzo and Dr Enriqueta Felip spoke with ecancer

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation